Danburstotug

DB19064InvestigationalProtein Based Therapies

Danburstotug is under investigation in clinical trial NCT04809012 (Study of STI-3031 in Patients With Selected Relapsed or Refractory Solid Tumors).

Mechanism
Curator reviewed
Also known as
Immunoglobulin g1, anti-(human programmed death-ligand 1) (human monoclonal sti-3031 .gamma.1-chain), disulfide with human monoclonal sti-3031 .lambda.-chain, dimer
Code names
IMC-001 · STI-3031

Resolves to

Compound
UNIIF44C4N45HGCAS2307144-65-4
Targets
Q9NZQ7CD274

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
11Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Danburstotug, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In